Verslagen

Voortgangsverslag

Samenvatting
Dit item is dichtgeklapt
Dit item is opengeklapt

In het oorspronkelijke voorstel werd het onderzoek opgedeeld in fase 1 (pre-vaccinatie) waarin humorale en cellulaire immuniteit tegen Sars-CoV-2 in de tijd werd vervolgd. In fase 2 (pre/post vaccinatie) waarin patiënten en gezonden met en zonder eerder doorgemaakt COVID vergeleken worden. Mede door sneller dan verwacht start van vaccinatie schema verlopen fase 1 en fase 2 in het huidige ondezoeksopzet parallel aan elkaar. Verder is de studie uitgebreid om de invloed van verschillende afweeronderdrukkende medicatie op de vaccinatieresponsen te onderzoeken. De meeste deelnemers met auto-immuunaandoeningen worden in de periode April-Juni gevaccineerd. We verwachten de eerste resultaten in Juli/Augustus 2021.

Resultaten
Dit item is dichtgeklapt
Dit item is opengeklapt

De eerste resultaten worden verwacht in juli/augustus 2021.

Samenvatting van de aanvraag

Samenvatting
Dit item is dichtgeklapt
Dit item is opengeklapt

Understanding of the maintenance of SARS-CoV-2-specific immunity after primo-infection (SIAP) is pertinent to address the risk of re-infection. However, it is unknown how long adaptive SIAP will last. This uncertainty is even more pressing for a large group of vulnerable immune-suppressed patients (ISP) who are at risk for severe disease when immunological memory is insufficient, as these patients may have less SIAP than healthy controls. In addition, there is a chance that the much-awaited national vaccination program against SARS-CoV-2 to protect the individual persons and to pursue herd immunity will be less effective in these patients, based on previous vaccinations against other pathogens. The objective of this study is to elucidate whether the course of SARS-CoV-2-specific immunity over time differs in ISP compared to healthy persons and whether the efficacy of SARS-CoV-2-targeted vaccination is reduced in these patients. We will thus provide valuable insights in the normal course of humoral and cellular immunity in healthy people and ISP, making the comparative results relevant for the whole society. To achieve this we will use the unique platform of our T2B consortium, a well-established close collaboration and infrastructure of 6 different academic hospitals, RIVM and Sanquin Blood Supply Foundation. We will build on several clinical studies already initiated by our clinical T2B partners to perform in-depth analysis of the humoral and cellular infection-induced and vaccine-induced immunity against SARS-CoV-2. In this prospective observational study we will collect longitudinal clinical data and samples that will be used to stratify for determining the vaccination efficacy, in ISP and healthy controls, with and without previous SARS-CoV-2 infection. Our data aim to provide guidance on medication adjustments to optimize SIAP and vaccination efficacy and to specify need for social distancing measures, not only for the vulnerable, but for the whole community.

Naar boven
Direct naar: InhoudDirect naar: NavigatieDirect naar: Onderkant website